Rehmann Capital Advisory Group’s Pacira BioSciences PCRX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,217	Closed	-$96.4K	–	1990
2019 Q2	$96.4K	Hold	2,217	–	–	0.01%	623
2019 Q1	$84.4K	Hold	2,217	–	–	0.01%	648
2018 Q4	$95.4K	Buy	2,217 +492	+29%	+$23K	0.01%	414
2018 Q3	$84.8K	Hold	1,725	–	–	0.01%	627
2018 Q2	$55.3K	Buy	1,725 +666	+63%	+$23K	0.01%	740
2018 Q1	$33K	Buy	+1,059	New	+$37.7K	0.01%	907

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rehmann Capital Advisory Group's PCRX Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 2,217 shares — an estimated $96.4K sold.

Rehmann Capital Advisory Group first reported a position in PCRX in Q1 2018 and held it in 6 quarters. The position peaked at $96.4K in Q2 2019. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 2,217 Pacira BioSciences shares in Q3 2019, an estimated $96.4K.
Rehmann Capital Advisory Group first reported a position in Pacira BioSciences in Q1 2018 and held it in 6 quarters.
Rehmann Capital Advisory Group's Pacira BioSciences position peaked at $96.4K in Q2 2019.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.